{"version":"https://jsonfeed.org/version/1.1","title":"Anecdotal — Wellness Intelligence","home_page_url":"https://anecdotal.health","feed_url":"https://anecdotal.health/feed.json","description":"Source-backed longevity, supplement, treatment, diagnostic and wellness-travel intelligence.","language":"en-GB","items":[{"id":"https://anecdotal.health/story/best-longevity-retreats-spain-2026-compared","url":"https://anecdotal.health/story/best-longevity-retreats-spain-2026-compared","title":"Best longevity retreats in Spain for 2026? Four programmes compared","summary":"SHA, RoseBar, Atzaró and ZEM all use the language of longevity. The actual experiences range from medical programmes to bookable spa circuits.","content_text":"There is no single best longevity retreat in Spain. SHA and ZEM present intensive, multi-day health programmes; RoseBar combines diagnostics with short or longer stays; Atzaró offers the most accessible entry point through individually priced spa sessions and a €270 longevity day.\n\n“Longevity retreat” now covers everything from a spa afternoon to medically supervised programmes costing thousands. Comparing oversight, diagnostics, treatments, duration and price is more useful than comparing branding.\n\nHow the four programmes differ\n\nSHA Spain in Alicante describes a medically oriented health-optimisation model that brings together diagnostics, precision medicine, nutrition and a wide treatment menu. It is the clearest fit for someone seeking a structured residential programme with clinical infrastructure, although the provider’s evidence and benefit claims still need to be assessed intervention by intervention.\n\nRoseBar at Six Senses Ibiza offers one-, three- and seven-day longevity programmes combining diagnostics, wellness technology and resort accommodation. Atzaró, also in Ibiza, takes a more modular approach: visitors can book a body scan, cryotherapy, infrared-bed session or a longevity day without committing to a full residential programme. ZEM Wellness Clinic in Altea positions itself at the intensive luxury end, with multi-day longevity programmes combining medical, nutritional and spa components.\n\nWhat to compare before booking\n\nAsk which clinicians are involved, which tests are included, which therapies are optional and which claimed benefits are supported by evidence. A body-composition scan, a massage and an intravenous treatment do not carry the same evidence or risk profile simply because they appear in one itinerary.\n\nPricing should be requested as an itemised programme rather than a headline package. Check what is included in accommodation, consultations, laboratory work, follow-up and treatment. Anecdotal’s comparison does not rank medical outcomes; it shows how the programmes differ so readers can ask better questions.","image":"https://anecdotal.health/images/homepage/longevity-lifestyle-2.jpg","date_published":"2026-07-27T12:00:00Z","date_modified":"2026-07-27T12:00:00Z","tags":["retreats","longevity","treatments","Spain","Editorial comparison"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/supplement-questions-womens-wellness-2026","url":"https://anecdotal.health/story/supplement-questions-womens-wellness-2026","title":"Four supplement questions shaping women’s wellness in 2026","summary":"Creatine, menopause products, vitamin D and pregnancy formulations are drawing attention—but the evidence and rules are not interchangeable.","content_text":"The most useful 2026 women’s-supplement questions are not “what is everyone taking?” but what population was studied, which formulation was used, whether a claim is legally authorised and whether pregnancy, menopause or medication changes the risk.\n\nWomen’s wellness marketing often compresses very different life stages into one market. Separating perimenopause, pregnancy, training and general nutrition prevents a trend from looking like universal guidance.\n\nCreatine interest is moving beyond sports nutrition\n\nA randomized double-blind study published in 2026 examined low-dose creatine formulations in 36 perimenopausal and postmenopausal women. That makes the study relevant to a fast-growing conversation, but its small sample and specific formulations limit what can be generalized. It does not make every creatine product a menopause product.\n\nThe useful questions are whether an outcome was pre-specified, how large the difference was, whether it held across groups and whether another study reproduced it. Product marketing often moves faster than that replication process.\n\nLife stage changes the supplement conversation\n\nThe UK Food Standards Agency’s June 2026 consumer guidance distinguishes situations where official advice exists—such as folic acid around early pregnancy and vitamin D during autumn and winter—from broader commercial claims. It also states that supplements are not medicines and cannot be marketed to treat symptoms such as menopause symptoms.\n\nThe practical filter is simple: identify the life stage, the nutrient or ingredient, the evidence population, the formulation and possible interactions. “For women” on a label is a marketing category; it is not evidence that every woman has the same need.","image":"https://anecdotal.health/images/homepage/collagen-lifestyle-1-v2.png","date_published":"2026-07-27T12:00:00Z","date_modified":"2026-07-27T12:00:00Z","tags":["womens-health","supplements","research","Global","Official guidance"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/switzerland-longevity-programmes-utolife-seven-springs-2026","url":"https://anecdotal.health/story/switzerland-longevity-programmes-utolife-seven-springs-2026","title":"Two new Swiss longevity models: a twelve-month clinic and a private members’ club","summary":"UtoLife and Seven Springs use the same category language but sell fundamentally different relationships.","content_text":"UtoLife markets a physician-led twelve-month programme in Zurich, while Seven Springs presents a private wellness club combining events, retreats, practitioners and member access.\n\nThe longevity market is expanding beyond one-off clinic stays into subscriptions, annual programmes and private communities.\n\nThe two business models\n\nUtoLife describes its Genesis programme as a physician-led, twelve-month sequence of ten integrated clinical interventions. The emphasis is longitudinal assessment and programme continuity rather than a short retreat.\n\nSeven Springs describes a private club that brings together practitioners, retreats, events, premium brands and a member community. Its current programming includes a women’s longevity retreat and time-limited founding membership pricing.\n\nWhy the category is changing\n\nA longer relationship can create better follow-up and more consistent measurement, but it also creates a larger financial commitment and more personal data. Consumers should understand which services are medical, which are hospitality and which are community benefits.\n\nThese models suggest that high-end longevity is adopting the economics of private clubs and subscriptions, not only destination spas.","image":"https://anecdotal.health/images/homepage/longevity-tile.jpg","date_published":"2026-07-26T12:00:00Z","date_modified":"2026-07-26T12:00:00Z","tags":["retreats","companies","longevity","Switzerland","Provider information"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/moringa-powder-salmonella-outbreak-closed-july-2026","url":"https://anecdotal.health/story/moringa-powder-salmonella-outbreak-closed-july-2026","title":"The US moringa-powder Salmonella outbreak is over—but recalled products may remain","summary":"The FDA and CDC closed the investigation after 131 reported cases across 38 states. The products have long shelf lives.","content_text":"The investigation closed on 22 July 2026 after 131 reported infections, including 36 hospitalisations and no deaths. Recalled powders and capsules may still be in homes because their expiry dates run into 2028.\n\nAn outbreak can be declared over while the underlying products remain usable and stored. Consumers need the affected brands and lot guidance, not only the closure headline.\n\nWhat the final update says\n\nThe FDA and CDC linked illnesses to recalled dietary supplements containing moringa leaf powder imported from India. Of 84 people interviewed across the investigation, 74 reported consuming a product containing moringa powder. Testing identified outbreak strains in finished products and ingredient samples.\n\nThe recalled list includes Live it Up Super Greens products and products from Why Not Natural and TNVitamins. Because some products carry expiry dates from August 2026 to January 2028, the FDA continues to tell consumers and retailers not to eat, sell or serve the affected products.\n\nWhat changed—and what did not\n\nThe outbreak investigation is complete, which means investigators are no longer identifying ongoing illnesses connected to current exposure. It does not mean recalled stock has automatically disappeared. The FDA has increased screening of imported moringa powder from India for Salmonella.\n\nAnyone checking a product should use the FDA page for the current brand, lot and expiry details. Anecdotal does not reproduce partial recall tables because they can change and should not replace the regulator’s live notice.","image":"https://anecdotal.health/images/homepage/ashwagandha-primary.png","date_published":"2026-07-22T12:00:00Z","date_modified":"2026-07-22T12:00:00Z","tags":["safety","supplements","United States","Regulatory action"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/samsung-galaxy-watch-9-ultra-2-health-features","url":"https://anecdotal.health/story/samsung-galaxy-watch-9-ultra-2-health-features","title":"Samsung’s new watches put five overnight signals into one daily health view","summary":"Galaxy Watch9 and Ultra2 add a Vitals baseline, Heart Health Score and updated sleep-apnoea analysis. Availability begins 7 August.","content_text":"Samsung’s Galaxy Watch9 and Watch Ultra2 combine heart rate, heart-rate variability, respiratory rate, skin temperature and blood oxygen into a Vitals baseline, alongside new training and heart-health summaries.\n\nWearable companies are moving from showing individual measurements to interpreting multiple signals at once. That can make data easier to use, but the resulting scores still depend on proprietary models and stated intended uses.\n\nWhat Samsung announced\n\nGalaxy Watch9 is aimed at continuous everyday health tracking, while Ultra2 is positioned for longer and more demanding training. Both connect to an updated Samsung Health experience built around Activity, Mindfulness, Nutrition, Sleep and Vitals.\n\nThe Vitals view compares five overnight measurements with a personalised baseline. Heart Health Score combines activity, sleep, body composition and stress trends. Fitness Index and Daily Cardio Load are intended to contextualise training volume and recovery.\n\nThe interpretation layer is the real product\n\nThe notable shift is not another sensor. It is the attempt to turn several noisy measurements into a smaller number of decisions and prompts. That is useful only if users can understand what a score represents, when it changes and where the boundary lies between general wellness and medical interpretation.\n\nSamsung says an updated sleep-apnoea feature analyses breathing disruptions and builds on an FDA-authorised feature introduced previously. Availability, regulatory status and feature support can vary by country and device.","image":"https://anecdotal.health/images/editorial/wearable-health-dashboard.png","date_published":"2026-07-22T12:00:00Z","date_modified":"2026-07-22T12:00:00Z","tags":["diagnostics","companies","longevity","Global","Company announcement"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/samsung-health-assistant-beta-2026","url":"https://anecdotal.health/story/samsung-health-assistant-beta-2026","title":"Samsung launches an AI health assistant inside Samsung Health","summary":"The US beta connects wearable data, Energy Score and conversational guidance in one interface.","content_text":"Samsung Health Assistant is a US beta that lets eligible users ask questions about data from Samsung Health and supported Galaxy wearables, while receiving AI-generated guidance inside the app.\n\nHealth dashboards are becoming conversational. That makes the boundary between explaining personal data and giving medical guidance more important and more visible.\n\nWhat the beta is designed to do\n\nSamsung says the assistant connects information that is otherwise spread across devices, apps and health categories. Eligible users can ask questions and receive guidance that draws on Samsung Health data and features such as Energy Score.\n\nThe announcement positions the assistant as a bridge between collecting data and understanding it. It does not remove the need to distinguish general wellness prompts from medical interpretation.\n\nWhat to watch during the rollout\n\nThe important details will be how Samsung communicates uncertainty, which data leaves the device, how long conversational health information is retained and what the product does when a user asks about symptoms or treatment.\n\nAnecdotal will update this record as eligibility, privacy documentation and independent testing become clearer.","image":"https://anecdotal.health/images/homepage/cognition-lifestyle-2.jpg","date_published":"2026-07-21T12:00:00Z","date_modified":"2026-07-21T12:00:00Z","tags":["companies","diagnostics","United States","Company announcement"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/who-dementia-risk-reduction-guidelines-2026","url":"https://anecdotal.health/story/who-dementia-risk-reduction-guidelines-2026","title":"WHO updates dementia-risk guidance and adds air pollution to the picture","summary":"The 2026 guidance says as much as 45% of dementia risk may be attributable to modifiable factors across the life course.","content_text":"WHO’s updated guidance emphasises physical activity, tobacco and alcohol reduction, diet, social connection and management of conditions such as high blood pressure and diabetes, while adding a recommendation to reduce air-pollution exposure.\n\nLongevity marketing often focuses on expensive tests and products. The updated global guidance puts much of the preventable risk conversation back on long-term behaviours and public-health conditions.\n\nWhat changed in the guidance\n\nWHO’s revised guidance brings together evidence on behaviours, social conditions, environmental exposure and noncommunicable disease. A new air-pollution recommendation broadens the frame beyond individual consumer choices.\n\nThe organisation estimates that more than 57 million people live with dementia worldwide, with close to 10 million new diagnoses each year. The “up to 45%” figure refers to the share of risk associated with modifiable factors; it does not mean every individual can remove 45% of their personal risk.\n\nWhy this matters to the wellness market\n\nConsumer longevity products frequently imply that more measurement or supplementation equals prevention. The WHO guidance instead highlights activity, tobacco, alcohol, diet, social isolation, cardiovascular and metabolic health, and the environment.\n\nThose interventions are not all simple or individually controllable. Air quality and access to prevention are policy questions as well as lifestyle questions. That distinction is easy to lose in consumer wellness coverage.","image":"https://anecdotal.health/images/homepage/cognition-lifestyle-1.jpg","date_published":"2026-07-15T12:00:00Z","date_modified":"2026-07-15T12:00:00Z","tags":["longevity","research","safety","Global","Official guidance"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/fda-import-alert-supplements-undeclared-drug-ingredients-2026","url":"https://anecdotal.health/story/fda-import-alert-supplements-undeclared-drug-ingredients-2026","title":"FDA expands its import alert for supplements containing undeclared drug ingredients","summary":"The July update covers products marketed for sexual enhancement, weight loss, muscle building and other uses.","content_text":"The FDA’s 9 July import alert allows listed products marketed as foods or supplements to be detained without physical examination when they contain undeclared active pharmaceutical ingredients.\n\nThe risk is not only that a claim is exaggerated. Some products sold as supplements can contain drug ingredients that are absent from the label, changing interaction and dosing risk.\n\nWhat the alert covers\n\nFDA investigations and laboratory analyses have identified products marketed as dietary supplements that contain undeclared pharmaceutical ingredients. The alert describes examples including anticoagulants, anticonvulsants and cholesterol-lowering drugs, alongside products promoted for weight loss, sexual enhancement and muscle building.\n\nProducts can be detained at the border when they meet the alert’s criteria. The live FDA record contains the affected firms and products; that operational list is more useful than a static reproduction.\n\nWhy labels cannot answer every safety question\n\nAn undeclared ingredient creates a different problem from a weak evidence claim. Consumers and clinicians cannot account for interactions or exposure if the active substance is missing from the label.\n\nAnecdotal treats these notices as safety updates, not as general judgments about every product in the same category. The relevant questions are the named product, manufacturer, ingredient finding and current regulatory action.","image":"https://anecdotal.health/images/homepage/performance-primary.png","date_published":"2026-07-09T12:00:00Z","date_modified":"2026-07-09T12:00:00Z","tags":["safety","supplements","United States","Regulatory action"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/exercise-trained-muscle-molecular-aging-study-2026","url":"https://anecdotal.health/story/exercise-trained-muscle-molecular-aging-study-2026","title":"Long-term training leaves a measurable signature in ageing human muscle","summary":"A July Nature Aging study mapped energy metabolism and exercise response in trained and untrained muscle.","content_text":"Researchers found that sustained physical training was associated with younger-looking molecular profiles, preserved energy metabolism and a stronger exercise response in human skeletal muscle.\n\nThe study adds molecular detail to a familiar longevity message: training status changes how ageing muscle behaves. It does not reduce exercise to a single biomarker or supplement target.\n\nWhat was measured\n\nThe study examined molecular ageing, energy metabolism and acute exercise response in human muscle. The trained group showed profiles consistent with delayed molecular ageing and better-preserved metabolic function.\n\nThe publication also provides an atlas for studying how fitness changes age-related biology. That dataset may be valuable beyond the headline comparison because it lets researchers inspect pathways rather than relying on one summary score.\n\nHow to read the result\n\nA molecular signature is not the same as a guarantee of longer life, and trained populations can differ from untrained populations in many ways. The study is best read as mechanistic human evidence supporting the relationship between sustained training and healthier muscle ageing.\n\nIt also provides a useful counterweight to product-led longevity coverage: one of the strongest signals in the field remains repeated physical training over time.","image":"https://anecdotal.health/images/homepage/performance-lifestyle-2.jpg","date_published":"2026-07-03T12:00:00Z","date_modified":"2026-07-03T12:00:00Z","tags":["research","longevity","Global research","Human research"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/senescent-cell-atlas-human-aging-2026","url":"https://anecdotal.health/story/senescent-cell-atlas-human-aging-2026","title":"Scientists begin mapping senescent cells across the human lifespan","summary":"The first large-scale atlas shows that cells described under one ageing label can have different molecular patterns in different tissues.","content_text":"NIH-funded researchers created tools and atlases to identify different senescent-cell states across human tissues, including a catalogue built from 14 human cell types.\n\n“Senescent cells” are often discussed as one target in longevity marketing. The new work reinforces that they are heterogeneous and that location, cell type and biological context matter.\n\nWhat the researchers built\n\nThe Cellular Senescence Network is developing public atlases of cells that stop dividing but remain biologically active. One team created the Senescence Catalog, or SenCat, using gene-activity and protein patterns across 14 types of human senescent cells.\n\nThe work identified distinct “senotypes” as well as pathways that appeared across several cell types. Other teams examined circulating signatures and the spatial organisation of immune ageing in lymph nodes.\n\nWhat the work does not establish\n\nThe atlas may improve future measurement and target selection, but it does not validate a supplement, drug or clinic treatment marketed as “senolytic.” Mapping a biological state is an earlier step than showing that changing it improves meaningful outcomes in people.\n\nThat gap—between a compelling mechanism and a demonstrated consumer benefit—is one of the most important distinctions in longevity coverage.","image":"https://anecdotal.health/images/homepage/longevity-primary.jpg","date_published":"2026-07-01T12:00:00Z","date_modified":"2026-07-01T12:00:00Z","tags":["research","longevity","Global research","Early research"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/uk-food-supplement-guidance-june-2026","url":"https://anecdotal.health/story/uk-food-supplement-guidance-june-2026","title":"The UK has rewritten its consumer guide to food supplements","summary":"The June guidance explains authorised claims, interactions and why supplement labels cannot promise to treat symptoms.","content_text":"The UK Food Standards Agency’s new consumer guide says supplements add to the normal diet, do not replace a balanced diet and cannot legally be marketed as treating, preventing or curing medical conditions or symptoms.\n\nThe guidance provides a useful baseline for judging UK supplement marketing—especially menopause, pregnancy and medication-related claims.\n\nThe practical points\n\nThe guidance defines food supplements, explains common formats and points consumers to the Great Britain register of authorised nutrition and health claims. It distinguishes supplements from medicines and states that treatment or cure claims are not permitted.\n\nIt also highlights situations that require more caution, including pregnancy, breastfeeding, medical conditions and prescription use. The page directs people to report suspected adverse reactions or product concerns through the appropriate channels.\n\nWhy “natural” is not the key test\n\nThe useful consumer checks are ingredient identity, amount, authorised claims, product origin, interaction potential and whether the seller is making medicine-like promises. A natural origin does not answer those questions.\n\nFor Anecdotal, the guidance becomes a reference point attached to relevant UK supplement stories rather than a generic disclaimer hidden in the footer.","image":"https://anecdotal.health/images/homepage/ashwagandha-lifestyle-2-v2.png","date_published":"2026-06-25T12:00:00Z","date_modified":"2026-06-25T12:00:00Z","tags":["supplements","safety","womens-health","United Kingdom","Official guidance"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/sha-spain-visiting-masters-womens-longevity-2026","url":"https://anecdotal.health/story/sha-spain-visiting-masters-womens-longevity-2026","title":"SHA Spain tests a visiting-expert format for women’s longevity and cognition","summary":"The three-day June residency combined masterclasses, private sessions and a guest programme inside the resort.","content_text":"SHA Spain’s first Visiting Masters residency brought a women’s-health specialist and a neuroscience researcher into the property for talks, consultations and guest programming from 18–20 June 2026.\n\nLuxury wellness properties are increasingly selling temporary access to recognised experts, not only treatments and accommodation.\n\nWhat the residency included\n\nSHA’s provider materials describe masterclasses, small-group conversations, a private dinner and a limited number of one-to-one sessions for guests staying during the residency. Themes included women’s longevity, hormonal health, cognitive performance and preventive wellbeing.\n\nThe programme was available only for three days, making it closer to an expert residency than a permanent clinic service.\n\nThe wider market signal\n\nWellness travel is moving toward event-like programming: a known expert, limited dates and a tightly framed subject can make a repeat property feel new. It also gives providers a way to test demand before creating a permanent department.\n\nFor consumers, the important distinction is whether a session is education, a clinical consultation or a treatment, and what follow-up exists after the stay.","image":"https://anecdotal.health/images/homepage/longevity-secondary.jpg","date_published":"2026-06-18T12:00:00Z","date_modified":"2026-06-20T12:00:00Z","tags":["retreats","womens-health","companies","Spain","Provider information"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/atzaro-ibiza-longevity-spa-prices-2026","url":"https://anecdotal.health/story/atzaro-ibiza-longevity-spa-prices-2026","title":"Atzaró turns ‘longevity’ into bookable Ibiza spa sessions","summary":"The menu ranges from €50 cryotherapy to a €270 longevity day, making the category visible at treatment level.","content_text":"Atzaró’s 2026 Ibiza menu sells individual body scanning, hypoxia, infrared, cryotherapy and training sessions, plus a €270 day experience combining several services with spa access and lunch credit.\n\nTransparent à-la-carte prices make it easier to see what a longevity-labelled experience actually contains—and which claims belong to the provider.\n\nWhat is on the menu\n\nAtzaró lists 3D body scanning, hypoxia sessions, an infrared bed, cryotherapy, a contrast circuit and personal training. Its longevity day combines a scan, infrared session, cryotherapy, spa access, a class and food-and-beverage credit.\n\nThe transparent menu makes the experience easier to compare with a residential programme. It is possible to book one modality without purchasing a week of accommodation and consultations.\n\nWhat the price list cannot establish\n\nThe provider describes benefits for recovery, inflammation, circulation and cellular function. Those are provider claims and need to be evaluated separately for each modality and protocol.\n\nPrice transparency is valuable, but it is not evidence of effectiveness. Anecdotal keeps the provider’s description, the commercial status and the evidence question visibly separate.","image":"https://anecdotal.health/images/homepage/longevity-lifestyle-1.jpg","date_published":"2026-06-12T12:00:00Z","date_modified":"2026-07-01T12:00:00Z","tags":["retreats","treatments","companies","Ibiza, Spain","Provider information"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/oura-health-radar-lab-uploads-2026","url":"https://anecdotal.health/story/oura-health-radar-lab-uploads-2026","title":"Oura is moving from sleep scores toward health monitoring and lab context","summary":"Health Radar rolls out through July, while lab-result uploads place blood biomarkers beside ring data.","content_text":"Oura’s 2026 software release adds Health Radar, live activity tracking, PDF lab uploads, GLP-1 insights and more granular data deletion to Ring Gen3 and newer devices.\n\nWearables are becoming containers for more sensitive and more clinically adjacent information. The product question is shifting from measurement accuracy alone to interpretation, privacy and escalation.\n\nWhat is being added\n\nHealth Radar is designed to monitor cardiovascular and respiratory patterns in the background. Oura says it will surface blood-pressure signals and a 30-day view of night-time breathing. Lab Uploads allow members to place PDF blood results alongside wearable metrics.\n\nThe release also includes live workout tracking, GLP-1-related insights, device location and the ability to delete data from a selected time period without deleting an account.\n\nThe new privacy and interpretation questions\n\nA ring that stores sleep and movement data is already sensitive. Adding laboratory results and AI-enabled health interpretation increases the consequences of account compromise, unclear retention or overconfident guidance.\n\nThe useful evaluation should therefore include privacy controls, country availability, intended use, validation and what happens when the system detects a pattern worth escalating—not only how many features appear in the app.","image":"https://anecdotal.health/images/homepage/cognition-secondary.jpg","date_published":"2026-05-28T12:00:00Z","date_modified":"2026-07-01T12:00:00Z","tags":["diagnostics","companies","longevity","Selected global markets","Company announcement"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/deepskin-aesthetic-stimulator-fda-clearance-2026","url":"https://anecdotal.health/story/deepskin-aesthetic-stimulator-fda-clearance-2026","title":"DeepSkin receives US clearance as an aesthetic electrical stimulator","summary":"The FDA database lists the DEP100 as substantially equivalent in a May 2026 decision.","content_text":"The FDA’s 510(k) database records DeepSkin DEP100 as a transcutaneous electrical stimulator for aesthetic purposes, with a substantially-equivalent decision dated 8 May 2026.\n\n“FDA cleared” describes a specific device, intended use and regulatory route. It should not be stretched into proof for every claim made around a treatment.\n\nWhat the database confirms\n\nThe FDA record identifies the device classification as a transcutaneous electrical stimulator for aesthetic purposes. The 510(k) decision is listed as substantially equivalent, with the application reviewed under the Neurology panel.\n\nThat record confirms a regulatory pathway and device identity. It does not by itself tell a consumer how large an aesthetic effect to expect, how results compare with alternatives or whether a particular clinic is using the cleared device as labelled.\n\nHow to read aesthetic-device claims\n\nCheck the exact device name, cleared indication, treatment protocol, operator qualifications, contraindications and the evidence supporting the promised outcome. “FDA registered,” “FDA cleared” and “FDA approved” are not interchangeable.\n\nAnecdotal links to the regulator’s record so the status can be checked independently rather than relying on a clinic’s summary.","image":"https://anecdotal.health/images/homepage/peptides-lifestyle-1.jpg","date_published":"2026-05-08T12:00:00Z","date_modified":"2026-07-13T12:00:00Z","tags":["treatments","diagnostics","safety","United States","Regulatory action"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/ema-breakthrough-medical-device-pilot-2026","url":"https://anecdotal.health/story/ema-breakthrough-medical-device-pilot-2026","title":"Europe begins a pilot for earlier expert input on breakthrough medical devices","summary":"The EMA programme gives selected high-risk devices a route to scientific advice before wider expansion in 2027.","content_text":"The European Medicines Agency launched a 2026 pilot that lets selected manufacturers seek expert-panel input on breakthrough status and clinical evidence for high-risk medical devices.\n\nWellness and diagnostics increasingly overlap with regulated devices. The pilot illustrates how evidence review differs from consumer-product launch language.\n\nHow the pilot works\n\nThe programme offers selected manufacturers an expert view on whether a device qualifies as breakthrough technology and advice on the clinical evidence needed under the EU Medical Device Regulation.\n\nAn initial phase runs through July 2026. A broader application window begins in September, with later phases expected to cover additional device classes.\n\nWhy consumers should care\n\nA device can look and feel like a wellness product while making claims that bring it into a regulated category. Regulatory status depends on intended use, evidence and jurisdiction, not simply whether the product is sold in a clinic or app store.\n\nAnecdotal uses those distinctions on device pages so “available,” “cleared,” “CE marked” and “clinically validated” are not treated as interchangeable labels.","image":"https://anecdotal.health/images/homepage/peptides-secondary.jpg","date_published":"2026-04-28T12:00:00Z","date_modified":"2026-07-01T12:00:00Z","tags":["diagnostics","treatments","safety","European Union","Official guidance"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/fda-addall-xr-xl-supplement-warning-2026","url":"https://anecdotal.health/story/fda-addall-xr-xl-supplement-warning-2026","title":"FDA says Addall supplements contained undeclared stimulant-like ingredients","summary":"Testing found DMAA, DMHA and phenibut across two products; only one was voluntarily recalled.","content_text":"The FDA says Addall XR Shot and Addall XL capsules contained unlawful or undeclared ingredients. The company agreed to recall the shot but declined to recall the capsules, according to the April update.\n\nThe case shows why a supplement label may not reflect the actual pharmacological exposure—and why a voluntary recall can cover only part of a warning.\n\nWhat testing found\n\nFDA laboratory testing found undeclared 1,4-DMAA in both products. The shot also contained phenibut, which the agency says is not a lawful dietary-supplement ingredient, while the capsules contained DMHA.\n\nThe FDA describes cardiovascular and neurocognitive concerns associated with the ingredients and says the firm declined to recall the capsule product.\n\nHow to use the warning\n\nThis is a named-product alert, not a general statement about all energy or focus supplements. Consumers should use the FDA page for current product images and instructions because those details can change.\n\nThe broader signal is that stimulant-style supplement categories deserve ingredient-level scrutiny, particularly when marketing resembles prescription or illicit-drug effects.","image":"https://anecdotal.health/images/homepage/performance-secondary.jpg","date_published":"2026-04-03T12:00:00Z","date_modified":"2026-04-03T12:00:00Z","tags":["safety","supplements","United States","Regulatory action"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]},{"id":"https://anecdotal.health/story/fda-menopause-hormone-therapy-label-changes-2026","url":"https://anecdotal.health/story/fda-menopause-hormone-therapy-label-changes-2026","title":"FDA changes boxed-warning language on six menopause hormone-therapy products","summary":"The February decision removed specific cardiovascular, breast-cancer and probable-dementia statements from the most prominent warning box.","content_text":"The FDA approved labelling changes to six menopausal hormone-therapy products in February 2026, including removal of selected risk statements from the boxed warning.\n\nThe change affects prescription-product communication, not supplement marketing, and it does not make every hormone product or treatment interchangeable.\n\nWhat the FDA changed\n\nThe agency approved changes to six menopausal hormone-therapy labels. Its announcement says selected statements concerning cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning.\n\nA boxed-warning change is a regulatory communication decision tied to specific approved products and evidence. It is not a blanket statement that hormone therapy has no risks or that every formulation has the same profile.\n\nWhy the distinction matters online\n\nNews headlines can turn a label change into a binary argument about whether hormone therapy is good or bad. The actual questions include product, route, dose, timing, indication, individual history and alternative options.\n\nThe update also should not be borrowed by supplement sellers making menopause-treatment claims. Prescription therapies and food supplements operate under different evidence and advertising rules.","image":"https://anecdotal.health/images/homepage/collagen-lifestyle-2-v2.png","date_published":"2026-02-12T12:00:00Z","date_modified":"2026-02-12T12:00:00Z","tags":["womens-health","treatments","safety","United States","Regulatory action"],"authors":[{"name":"Anecdotal Editorial","url":"https://anecdotal.health/about"}]}]}